Targets › CHEK2
1 program from 1 company in 2 trials: 2 Phase 2; Oncology; next expected readout May 2027.
Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. (UniProt, O96017)
Open in Phaseline: the race on CHEK2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Acrivon Therapeutics | Prexasertib (ACR-368) Serine/threonine-protein kinase Chk1 inhibitor; Serine/threonine-protein kinase Chk2 inhibitor | CHEK1, CHEK2 | Phase 2 | Endometrial Adenocarcinoma; Head and Neck Squamous Cell Carcinoma | May 2027 |
Endometrial Adenocarcinoma (1) Head and Neck Squamous Cell Carcinoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.